Compare EPAM Systems Inc (EPAM) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPAM Systems Inc vs Natera Inc. Common Stock — how do they compare? EPAM Systems Inc trades at $115.14 (market cap $5.96B), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 9.6× EPAM Systems Inc's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, EPAM Systems Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold EPAM Systems Inc for 37 Days and Natera Inc. Common Stock for 0 Days on average.
| EPAM | NTRA | |
|---|---|---|
Market Cap | $5.96B | $57.03B |
Volume | 731,369 | 1,131,157 |
Sector | Technology | Health |
52-Week High | $221.40 | $425.64 |
52-Week Low | $76.04 | $179.42 |
Typical Hold Time | 37 Days | 0 Days |
Enterprise Value | $5.32B | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPAM Systems trades at $114.63, up 1.41% today, with a bullish technical signal and strong fundamental valuation metrics including a P/E of 15.67 and P/S of 1.12. Recent quarterly earnings have consistently beaten expectations, and the company announced a partnership with Wiz to enhance cloud security (PRNewsWire, 2026-08-25).
The outlook is positive with a consensus price target of $119, representing ~4% upside. Key opportunities include AI-native revenue growth exceeding 11% (Seeking Alpha, 2026-09-02), while risks involve slower North American growth and activist pressure for buybacks (Reuters, 2026-08-31).
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EPAM Systems Inc
EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.
Read more on EPAM →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
